Salminen T M, Saarenmaa I E, Heikkilä M M, Hakama M
Tampere School of Public Health, University of Tampere, Finland.
Acta Oncol. 2000;39(8):969-72. doi: 10.1080/02841860050215954.
The aim of the study was to find out whether the effect of hormonal replacement therapy (HRT) is modified by the mammographic parenchymal patterns on the risk of breast cancer. Subjects were 4163 Finnish women aged 40-47 years at entry who were invited to breast cancer screening every second year from 1982 to 1990. Mammographic parenchymal patterns (Wolfe's classification) were recorded at each screening round. The information, on use of HRT, was recorded from 1984. The follow-up ended in 1993 and up until that time 68 new breast cancers were diagnosed. A Poisson regression model was used in the analysis of the data. Use of HRT was not related to the risk of breast cancer (RR = 0.7, 95% CI 0.4-1.4), whereas mammographic parenchymal pattern was statistically significantly associated with risk of breast cancer. The age-adjusted relative risk of breast cancer among women with P2 versus N1 pattern was 2.5 (95% CI 1.3-4.8) and with DY versus N1 pattern 4.9 (951% CI 1.6-15.1). Women using HRT and with DY pattern were at substantially increased risk of breast cancer (RR = 11.6, 95% CI 2.5-53.6) compared with women not using HRT and with N1 pattern. There was an increased risk of breast cancer among women with DY mammographic parenchymal pattern who used HRT, which was consistent with a synergistic joint effect.
该研究的目的是确定激素替代疗法(HRT)的效果是否会因乳腺钼靶实质模式对乳腺癌风险的影响而改变。研究对象为4163名芬兰女性,她们在入组时年龄为40 - 47岁,于1982年至1990年期间每两年被邀请参加一次乳腺癌筛查。每次筛查时记录乳腺钼靶实质模式(沃尔夫分类法)。从1984年开始记录HRT的使用信息。随访于1993年结束,截至那时共诊断出68例新发乳腺癌。数据分析采用泊松回归模型。使用HRT与乳腺癌风险无关(相对危险度RR = 0.7,95%置信区间CI 0.4 - 1.4),而乳腺钼靶实质模式与乳腺癌风险在统计学上有显著关联。与N1模式相比,P2模式女性的年龄调整后乳腺癌相对危险度为2.5(95% CI 1.3 - 4.8),DY模式女性与N1模式相比为4.9(95% CI 1.6 - 15.1)。与未使用HRT且为N1模式的女性相比,使用HRT且为DY模式的女性患乳腺癌的风险大幅增加(RR = 11.6,95% CI 2.5 - 53.6)。使用HRT的DY乳腺钼靶实质模式女性患乳腺癌的风险增加,这与协同联合效应一致。